The company's biotechnology platform focuses on developing novel treatments to improve pregnancy success rates and outcomes for women who have undergone multiple unsuccessful in vitro fertilization procedures. Nora's lead compound, NT100, is a biologic agent that optimizes maternal-fetal immune tolerance, which may better enable embryo implantation and pregnancy maintenance. The platform also aims to address IVF failure and recurrent pregnancy loss in women with a history of unexplained recurrent miscarriage, providing physicians with a solution to help their patients.